Abstract library

69 results for "VIPoma".
#244 Challenges in the Management of VIPoma Patients
Introduction: VIPomas are a rare neuroendocrine tumor (NET). 90% are pancreatic. 40-70% are metastatic at presentation. The VIPoma syndrome is characterized by secretory diarrhoea, hypokalaemia and achlorhydria.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr Fatima El-Khouly
#1248 Case Report of Recurrent VIPoma
Introduction: 51yr presented with 7 month diarrhoea&2 stone weight loss. All tests negative, only abnormality hypokalaemia. FGH profile: VIP raised>400, peptide histidine methionine>1000, GAWK of 250. Diagnosis of VIPoma. CT: 5cm mass tail & body of pancreas, no hepatic or adrenal lesions. Octreotide treatment started. Bowel frequency improved, hypokalaemia corrected. Octreotide scan showed uptake only in pancreas. Patient readmitted 5 months later hypokalaemic myopathy, K 1.7, surgical distal pancreatectomy & splenectomy completed. Histology: NET within pancreas, moderate cellular differentiation, variable mitotic rate.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Clinical cases/reports
Presenting Author: Dr Victoria Mulcahy
Authors: Mulcahy V, McStay M, Sizer B, ...
Keywords: VIPoma
#1261 Emergency Therapy for Liver Metastases from Advanced VIPoma: Surgery or Transarterial Chemoembolization
Introduction: VIPoma is a rare neuroendocrine tumor (NET) with a high potential to develop hepatic metastases and poor prognosis. The primitive tumor is non-symptomatic and usually localized within the pancreas. Liver metastasis drove the prognosis and induced profuse watery diarrhea or renal failure.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Johann Dréanic
#2245 Metastatic VIPOMA, Co-Secreting Insulin, with Complete Response to Lanreotide Combined with Capecitabine and Temozolamide
Introduction: VIPomas are rare neuroendocrine tumors (NETs) associated with vasoactive intestinal polypeptide (VIP) hypersecretion causing watery diarrhea, hypokalaemia and achlorhydria. They originate mostly in the pancreas and 60-80% are malignant. Hormonal co-secretion is rarely reported.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Case reports
Presenting Author: Bernardo Marques
#3003 The Proinflammatory Molecule, VAP-1, Is Enriched in the Stroma of Midgut NETs and Plaques of Carcinoid Heart Disease Valves
Introduction: Vascular adhesion protein-1 (VAP-1) is a novel driver of tissue inflammation and fibrosis.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dr Chris Weston
Authors: Shah T, Sagar V, Neil D, Liu B, ...
#1535 VIPomas, a Rare Entity
Introduction: VIP secreting pancreatic neuroendocrine tumors(pNETs) are rare and controlled studies are lacking.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: MD,PhD Georgios Boutzios
Keywords: VIPoma, pNET
#2110 Pancreatic VIPomas: Reported Cases From China Since 1980
Introduction: Vasoactive intestinal polypeptide (VIP)-secreting tumors (VIPoma) are rare neuroendocrine tumors with distinct clinic presentation.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Case reports
Presenting Author: MD Chuyan Chen
Authors: Chen C, Zheng Z, Xie Y, Zheng C, ...
Keywords: VIPoma, NET, somatostatin
#983 Vipomas: Report of Three Cases in Ten Years
Introduction: VIPoma is a rare neuroendocrine tumor (NET) with an incidence of one in 10 million per year. Most cases arise within the pancreas, with others reported in the lungs, colon, liver, adrenals, and neuroganglia.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Surgical treatment
Presenting Author: Prof. Claudio Pasquali
#1219 Changes in Neuroendocrine Tumor Microenvironment with WHO Tumor Grading
Introduction: The microenvironment of neuroendocrine neoplasias (NEN) in view of tumor grading (WHO classification of 2000 und 2010) has not yet been validated. Both classifications distinguish between well and poorly differentiated neuroendocrine tumors, including proliferation rate, mitotic index and histomorphology. The WHO classification of 2000 further evaluates tumor location, size, angioinvasion, invasion of the muscle layer, functionally active tumors and metastases.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Biomarkers
Presenting Author: Dr. med. Silke Cameron
Authors: Cameron S, Skupin J, Füzesi L, ...
Keywords: NEN stroma
#2955 Development of an EORTC Quality of Life Questionnaire for Patients with Pancreatic Neuroendocrine Tumours: Phases 1-3
Introduction: Measuring quality of life (QoL) in Pancreatic Neuroendocrine Tumours (pNET) involves assessing issues from symptoms, disease and treatment. The validated gastrointestinal NETs module (EORTC QLQ-GINET21) is used with EORTC QLQ-C30 but there are concerns it inadequately measures QoL in pNET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Non digestive NETs (bronchial, thymic, others) - diagnosis and therapy
Presenting Author: Elizabeth Friend